Written on 01/23/2020 by Benjamin Barber aka Endomorphosis

Here is a summary of the rate of the spread of the virus, projections into the future, the medication names and manufacturers for the disease.

https://en.wikipedia.org/wiki/2019%E2%80%9320_outbreak_of_novel_coronavirus_(2019-nCoV)#External_links

https://zh.wikipedia.org/wiki/2019%E6%96%B0%E5%9E%8B%E5%86%A0%E7%8B%80%E7%97%85%E6%AF%92

2019.12.31 27 suspected cases

2020.01.23 633 confirmed / 422 suspected cases 17 deaths

death rate = 17/633 = 2.68%

Doubling rate 4.581 days (of both confirmed and suspected cases)

Percent growth per day 15.1% (of both confirmed and suspected cases)

Compound interest calculation

Projected 30 day sick population 58,516

Projected 30 day deaths 1,568

Projected 60 day sick population 5,409,336

Projected 60 day deaths 144,970

Projected 90 day sick population 500,050,819

Projected 90 day deaths 13,401,361

(assuming constant growth rates)

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322919/

Interferon-β 1a and SARS Coronavirus Replication

Here, we report that recombinant human interferon (IFN)-β1a potently inhibits SARS coronavirus replication in vitro.

https://www.drugbank.ca/drugs/DB00060 human interferon (IFN)-β1a

https://www.nature.com/articles/srep01686

Inhibition of novel β coronavirus replication by a combination of interferon-α2b and ribavirin

Thus, a combination of interferon-α2b and ribavirin, which are already commonly used in the clinic, may be useful for patient management in the event of future nCoV infections.

https://www.drugbank.ca/drugs/DB00105 interferon-α2b

https://www.drugbank.ca/drugs/DB00811 ribavirin

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~

由Benjamin Barber aka Endomorphosis撰写于01/23/2020

这是病毒传播速度的摘要，对未来的预测，药物名称以及该疾病的生产商。

https://en.wikipedia.org/wiki/2019%E2%80%9320_outbreak_of_novel_coronavirus_(2019-nCoV)#External_links

https://zh.wikipedia.org/wiki/2019%E6%96%B0%E5%9E%8B%E5%86%A0%E7%8B%80%E7%97%85%E6%AF%92

2019.12.31 27宗怀疑个案

2020.01.23 284例确诊病例17人死亡

2019.12.31 27宗怀疑个案

2020.01.23 633例确诊病例/ 422例疑似病例17例死亡

死亡率= 17/633 = 2.68％

4.581天（已确诊和疑似病例）的加倍率

每天的增长率15.1％（在已确诊和疑似病例中）

复利计算

预计30天患病人口58,516

预计30天死亡人数1,568

预计60天患病人口5,409,336

预计60天死亡人数144,970

预计90天患病人口500,050,819

预计90天死亡人数13,401,361

（假设增长率恒定）

https://translate.google.com/translate?hl=&sl=en&tl=zh-CN&u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC3322919%2F

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3322919/

干扰素-β1a和SARS冠状病毒复制

在这里，我们报道重组人干扰素（IFN）-β1a在体外有效抑制SARS冠状病毒复制。

https://translate.google.com/translate?hl=&sl=en&tl=zh-CN&u=https%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00060%20

https://www.drugbank.ca/drugs/DB00060 人干扰素（IFN）-β1a

https://translate.google.com/translate?hl=&sl=en&tl=zh-CN&u=https%3A%2F%2Fwww.nature.com%2Farticles%2Fsrep01686

https://www.nature.com/articles/srep01686

干扰素-α2b和利巴韦林联用抑制新型β冠状病毒复制

因此，在临床上已经普遍使用的干扰素-α2b和利巴韦林的组合可能在将来发生nCoV感染时对患者进行治疗。

https://translate.google.com/translate?hl=&sl=en&tl=zh-CN&u=https%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00105%20

https://www.drugbank.ca/drugs/DB00105 干扰素-α2b

https://translate.google.com/translate?hl=&sl=en&tl=zh-CN&u=https%3A%2F%2Fwww.drugbank.ca%2Fdrugs%2FDB00811%20